Is First Tracks Biotherapeutics Inc (TRAX) a Buy, Sell, or Hold?
First Tracks Biotherapeutics Inc
NASDAQ:TRAX
$36.13 USD
$1.76 (5.12%)
- Volume
- 474.47K
- Average Volume
- 623.25K
- Market Capitalization
- $1.26B
- P/E Ratio
- -12.86
- Dividend Yield
- 0.00%
- Price Target
- $45.00
- Year High
- $38.49
- Year Low
- $14.72
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $8.74
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Daniel R. Faga |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | TRAX |
| CUSIP | 337185102 |
| CIK | 0002091349 |
| Web | https://www.firsttracksbio.com |
| Phone | 858 362 6295 |
| Currency | USD |
| Employees | 104 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 8.74 |
| Quick Ratio | 8.74 |
| Cash Ratio | 7.50 |
Sales & Book Value
| Annual Sales | -$ |
| Price / Sales | 0.00 |
| Cash Flow | -2.23 |
| Price / Cash Flow | -16.24 |
| Price / Book | 4.88 |
Price Target and Rating
| Average Stock Price Forecast | $45.00 |
| High Stock Price Forecast | $54.00 |
| Low Stock Price Forecast | $30.00 |
| Forecast Upside/Downside | -19.71% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 0 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $0 |
| Trailing P/E Ratio | -12.86 |
| PEG Ratio | -0.13 |
| P/E Growth | -0.13 |
| Net Income | -$166.09M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -30.10% |
| Return on Assets | -33.62% |
Financials Score
| AltmanZ Score | |
| Piotroski Score | |
| Working Capital | - |
| Total Assets | - |
| Ebit | - |
| Market Cap | - |
| Total Liabilities | - |
Poll Results
About First Tracks Biotherapeutics Inc (NASDAQ:TRAX) Stock
First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments. The firm is actively involved in the discovery and progression of therapeutics aimed at combating autoimmune and inflammatory disorders, currently advancing programs like rosnilimab, ANB033, and ANB101 through their clinical stages. ...
First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences
2026-05-21 16:15:00
SAN DIEGO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that Daniel Faga, president and chief executive officer, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences:
First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences
2026-05-21 16:15:00
SAN DIEGO, Calif. , May 21, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that Daniel Faga, president and chief executive officer, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences: 2026 Jefferies Global Healthcare Conference, New York Format - Presentation and one-on-one investor meetings Date and Time - Wednesday, June 3, 2026 at 12:15pm ET / 9:15am PT Leerink Partners Therapeutics Forum, Boston Format - One-on-one investor meetings Date and Time - Tuesday, July 14, 2026 A live webcast of the presentation will be available on the investor section of the First Tracks website at https://ir.
2026-05-14 16:15:00
SAN DIEGO, May 14, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.
First Tracks: Huge Cash Reserves Will Not Sustain Testing For Long
2026-05-06 04:13:07
First Tracks Biotherapeutics, spun off from AnaptysBio, launches with $180M cash and a diverse, early-stage pipeline. I rate TRAX as a Hold due to post-spin instability, near-term dilution risk, and a multi-year path to revenue. ANB033 targets celiac disease, with no current FDA-approved therapies; pivotal trial data are expected in Q4 2026–2027, with commercialization likely a decade away.
Frequently Asked Questions
-
What is the current First Tracks Biotherapeutics Inc (TRAX) stock price?
-
First Tracks Biotherapeutics Inc(NASDAQ:TRAX) stock price is $36.13 in the last trading session. During the trading session, TRAX stock reached the peak price of $38.49 while $14.72 was the lowest point it dropped to. The percentage change in TRAX stock occurred in the recent session was 5.12% while the dollar amount for the price change in TRAX stock was $1.76.
-
TRAX's industry and sector of operation?
-
The NASDAQ listed TRAX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of TRAX?
-
Paul F. Lizzul | Chief Medical Officer
Ajim A. Tamboli | Chief Financial Officer
Benjamin Stone | Chief Business Officer
Daniel R. Faga | CEO, President & Director
Eric J. Loumeau | Secretary -
How many employees does TRAX have?
-
Number of TRAX employees currently stands at 104. TRAX operates from 10770 Wateridge Circle, San Diego, CA 92121, US.
-
Link for TRAX official website?
-
Official Website of TRAX is: https://www.firsttracksbio.com
-
How do I contact TRAX?
-
TRAX could be contacted at phone #858 362 6295 and can also be accessed through its website. TRAX operates from 10770 Wateridge Circle, San Diego, CA 92121, US.
-
How many shares of TRAX are traded daily?
-
The average number of TRAX shares traded daily for last 3 months was 623.25K.
-
What is the market cap of TRAX currently?
-
The market value of TRAX currently stands at $1.26B with its latest stock price at $36.13